Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1970 1
1974 1
1977 1
1978 1
1979 1
1987 1
1988 1
1990 1
1994 3
1995 1
1998 1
2006 1
2010 1
2012 1
2013 5
2014 10
2015 27
2016 29
2017 27
2018 27
2019 18
2020 23
2021 26
2022 18
2023 25
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

214 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for l neiman
Your search for L Neisani retrieved no results
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Motzer R, et al. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. N Engl J Med. 2021. PMID: 33616314 Clinical Trial.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators. Motzer RJ, et al. N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25. N Engl J Med. 2015. PMID: 26406148 Free PMC article. Clinical Trial.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators. Motzer RJ, et al. Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Lancet Oncol. 2019. PMID: 31427204 Free PMC article. Clinical Trial.
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
Motzer RJ, Escudier B, McDermott DF, Arén Frontera O, Melichar B, Powles T, Donskov F, Plimack ER, Barthélémy P, Hammers HJ, George S, Grünwald V, Porta C, Neiman V, Ravaud A, Choueiri TK, Rini BI, Salman P, Kollmannsberger CK, Tykodi SS, Grimm MO, Gurney H, Leibowitz-Amit R, Geertsen PF, Amin A, Tomita Y, McHenry MB, Saggi SS, Tannir NM. Motzer RJ, et al. J Immunother Cancer. 2020 Jul;8(2):e000891. doi: 10.1136/jitc-2020-000891. J Immunother Cancer. 2020. PMID: 32661118 Free PMC article. Clinical Trial.
In memoriam: Harvey L. Neiman, MD.
Hillman BJ. Hillman BJ. Radiology. 2015 Feb;274(2):627. doi: 10.1148/radiol.14144053. Radiology. 2015. PMID: 25625750 No abstract available.
Who Will Pay for AI?
Chen MM, Golding LP, Nicola GN. Chen MM, et al. Radiol Artif Intell. 2021 Mar 3;3(3):e210030. doi: 10.1148/ryai.2021210030. eCollection 2021 May. Radiol Artif Intell. 2021. PMID: 34142090 Free PMC article.
The Neiman Imaging Comorbidity Index: Development and Validation in a National Commercial Claims Database.
Pelzl CE, Rosenkrantz AB, Rula EY, Christensen EW. Pelzl CE, et al. J Am Coll Radiol. 2024 Jan 18:S1546-1440(23)01018-9. doi: 10.1016/j.jacr.2023.12.003. Online ahead of print. J Am Coll Radiol. 2024. PMID: 38276924
OBJECTIVE: To build the Neiman Imaging Comorbidity Index (NICI), based on variables available in claims datasets, which provides good discrimination of an individual's chance of receiving advanced imaging (CT, MR, PET), and thus, utility as a control variable in research. …
OBJECTIVE: To build the Neiman Imaging Comorbidity Index (NICI), based on variables available in claims datasets, which provides good …
Increasing Subspecialization of the National Radiologist Workforce.
Rosenkrantz AB, Hughes DR, Duszak R Jr. Rosenkrantz AB, et al. J Am Coll Radiol. 2020 Jun;17(6):812-818. doi: 10.1016/j.jacr.2019.11.027. Epub 2019 Dec 31. J Am Coll Radiol. 2020. PMID: 31899181
Work relative value units associated with radiologists' billed claims were mapped to subspecialties using the Neiman Imaging Types of Service to classify radiologists as subspecialists when exceeding a 50% work effort in a given subspecialty and as generalists otherwise. . …
Work relative value units associated with radiologists' billed claims were mapped to subspecialties using the Neiman Imaging Types of …
MACRA 2.5: the legislation moves forward.
Golding LP, Nicola GN, Ansari SA, Rosenkrantz AB, Silva Iii E, Manchikanti L, Hirsch JA. Golding LP, et al. J Neurointerv Surg. 2018 Dec;10(12):1224-1228. doi: 10.1136/neurintsurg-2018-013910. Epub 2018 Jul 4. J Neurointerv Surg. 2018. PMID: 29973387 Review.
214 results